Diabetes-Associated Autoantibodies

Use in combination with another insulin antibody test to determine autoimmune DM.

Useful to establish autoimmune etiology in previously diagnosed T1DM.

  • Determine presence of antibodies to endogenous or exogenous insulin analogues
  • Testing not recommended for patients receiving insulin >2 weeks, as insulin antibody formation may occur

Useful to establish autoimmune etiology in previously diagnosed T1DM.

Useful to establish autoimmune etiology in previously diagnosed T1DM.

See Related Tests

Diabetes mellitus (DM) is a group of metabolic disorders characterized by hyperglycemia that results from defects in insulin secretion, insulin action, or both. Type 1 DM (T1DM) is less common than type 2 DM (T2DM) and is characterized by insulin deficiency, often resulting from the autoimmune-mediated destruction of insulin-producing cells. The detection of diabetes-associated autoantibodies confirms an autoimmune etiology for that individual.

Indications for Insulin Antibody Testing

Indications for Insulin Antibody Testing
  • Do not order individual antibody tests; order at least 2 antibodies if pursuing testing 
  • For most cases, use GAD in combination with ≥1 of the following antibodies: IA-2, IAA, ICA, ZnT8
T1DM
  • Patient should have diagnosed DM
    • Antibody testing is not useful for the diagnosis of DM
    • Patients should ideally be receiving insulin ≤2 weeks
      • Testing not recommended for patients receiving insulin >2 weeks, as insulin antibody formation may occur (false-positive result possible)
  • Most useful in children or in adults without traditional risk factors for T2DM 
    • Traditional risk factors include BMI ≥25 kg/m2, first-degree relative with diabetes, high-risk race/ethnicity, physical inactivity, etc. (for a full list of traditional risk factors, see Table 2.3 in the Standards of Medical Care in Diabetes—2019).
  • May be useful in difficult adult cases when it is unclear if patient has T1DM or T2DM 
T2DM

No indication for routine evaluation or management 
Screening

Acceptable only for first-degree relatives of a proband with T1DM or in research settings 
Limited Use
  • Differentiate LADA from T2DM 
  • Rule out autoantibodies as a cause of DM in patients with suspected genetic DM types (eg, monogenic DM, maturity onset diabetes of the young [MODY])

GAD, glutamic acid decarboxylase antibody; IA-2, islet antigen-2; IAA, insulin antibody; ICA, islet cell cytoplasmic antibody; LADA, latent autoimmune diabetes of the adult; ZnT8, zinc transporter 8 antibody

 Diabetes Mellitus Type 1 Overview

Prevalence

1.25 million in the United States

Age of Onset

Most common in children but can develop in individuals of any age, especially in late 30s or early 40s

Symptoms

  • Excessive thirst, hunger, and urination
  • Fatigue, nausea, blurred vision
  • Unexplained weight loss
  • Obesity is rare upon initial diagnosis
  • May have other autoimmune disorders

Physiology

  • Caused by autoimmune-mediated destruction of insulin-producing beta cells of the islets of Langerhans in the pancreas
  • Five major autoantibodies of diagnostic interest
    • Glutamic acid decarboxylase (GAD)
    • Insulin antibodies (IAA)
    • Islet antigen-2 (IA-2)
    • Islet-cell antibodies (ICA)
    • Zinc transporter 8 (ZnT8)
  • Antibodies may be present in individuals years before the onset of clinical symptoms
  • Presence of these antibodies in individuals with diabetes confirms an autoimmune etiology

Test Interpretation

Sensitivity/Specificity

Moderate sensitivity, high specificity in newly diagnosed T1DM

  • Presence of antibodies may decrease with prolonged disease
  • Insulin antibody testing loses specificity once patient has been on exogenous insulin for >2 weeks

Results

  • Presence of multiple insulin antibodies (GAD, IA-2, IAA, ICA, and ZnT8) is predictive of T1DM
  • If one autoantibody is found, others should be assayed; the risk of T1DM increases (>90%) if an individual tests positive for two or more autoantibodies
  • For further risk stratification, HLA-DR or HLA-DQ genotyping may be helpful

Limitations

  • Negative test results do not rule out autoimmune diabetes; autoantibody response varies in individuals
  • Presence of a single autoantibody in the absence of clinical symptoms has low predictive value (1-2% in healthy individuals)
  • Not all individuals with antibodies will develop T1DM
  • Do not use to monitor or diagnose T1DM
  • IAA test does not differentiate between antibodies specific for endogenous and exogenous forms of insulin
    References

  1. 25869408

    Handelsman Y

    Bloomgarden ZT

    Grunberger G

    Umpierrez G

    Zimmerman RS

    Bailey TS

    Blonde L

    Bray GA

    Cohen J

    Dagogo-Jack S

    Davidson JA

    Einhorn D

    Ganda OP

    Garber AJ

    Garvey T

    Henry RR

    Hirsch IB

    Horton ES

    Hurley DL

    Jellinger PS

    Jovanovi? L

    Lebovitz HE

    LeRoith D

    Levy P

    McGill JB

    Mechanick JI

    Mestman JH

    Moghissi ES

    Orzeck EA

    Pessah-Pollack R

    Rosenblit PD

    Vinik AI

    Wyne K

    Zangeneh F

    American Association of Clinical Endocrinologists and American College of Endocrinology - Clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015.

    Endocr Pract

    2015
    21 Suppl 1
    Jan-87
    PubMed
Related Information
Diabetes Mellitus